Evaluation of degarelix in the management of prostate cancer

References

• HugginsCStevensREJHodgesCVStudies in prostatic cancer II. The effects of castration on advanced carcinoma of the prostate glandArch Surg194143209223
   Google Scholar
• FDA, US Food and Drug AdministrationCancer drug approval endpoints for prostate cancer 2009 Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094586.htm; Accessed Nov 16 2009.
   Google Scholar
• FlemingMTMorrisMJHellerGScherHIPost-therapy changes in PSA as an outcome measure in prostate cancer clinical trialsNat Clin Pract Oncol200631265866717139317
   PubMedGoogle Scholar
• LiljaHUlmertDVickersAJProstate-specific antigen and prostate cancer: prediction, detection and monitoringNat Rev Cancer20088426827818337732
   PubMed Web of Science ®Google Scholar
• HuhtaniemiIWhiteRMcArdleCAPerssonBEWill GnRH antagonists improve prostate cancer treatment?Trends Endocrinol Metab2009201435019008119
   PubMed Web of Science ®Google Scholar
• RohlHFBeukeHPEffect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancerScand J Urol Nephrol199226111141631501
   PubMed Web of Science ®Google Scholar
• HeidenreichABollaMJoniauSGuidelines on Prostate CancerEuropean Association of Urology2009 Available from: http://www.uroweb.org/professional-resources/guidelines/online; Accessed Oct 26 2009.
   Google Scholar
• ConnPMCrowleyWFJrGonadotropin-releasing hormone and its analoguesN Engl J Med19913242931031984190
   PubMed Web of Science ®Google Scholar
• SasagawaIKubotaYNakadaTInfluence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostateInt Urol Nephrol199830674575310195870
   PubMedGoogle Scholar
• TomeraKGleasonDGittelmanMThe gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancerJ Urol200116551585158911342922
   PubMed Web of Science ®Google Scholar
• ThompsonIMZeidmanEJRodriguezFRSudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostateJ Urol19901446147914802122011
   PubMed Web of Science ®Google Scholar
• Van PoppelHNilssonSTestosterone surge: rationale for gonadotropin-releasing hormone blockers?Urology20087161001100618407326
   PubMed Web of Science ®Google Scholar
• PerlmutterMALeporHAndrogen deprivation therapy in the treatment of advanced prostate cancerRev Urol20079Suppl 1S3S817387371
   PubMedGoogle Scholar
• KaisaryAVIversenPTyrrellCJCarrollKMorrisTIs there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?Prostate Cancer Prostatic Dis20014419620312497018
   PubMed Web of Science ®Google Scholar
• HeidenreichHAusGAbbouCCGuidelines on prostate cancerEuropean Association of Urology2007 Available from: http://www.uroweb.org/fileadmin/user_upload/Guidelines/07_Prostate_Cancer_2007.pdf; Accessed Aug 10 2009.
   Google Scholar
• SharifiRBrownellerRSerum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancerJ Urol200216831001100412187208
   PubMed Web of Science ®Google Scholar
• ZinnerNRBidairMCentenoATomeraKSimilar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trialUrology20046461177118115596193
   PubMed Web of Science ®Google Scholar
• MoroteJOrsolaAPlanasJRedefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapyJ Urol20071784 Pt 11290129517698136
   PubMed Web of Science ®Google Scholar
• PerachinoMCavalliVBraviFTestosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?BJU Int2009828 [Epub ahead of print].
   Web of Science ®Google Scholar
• JockenhovelFBhasinSSteinerBSRivierJEValeWWSwerdloffRSHormonal effects of single gonadotropin-releasing hormone antagonist doses in menJ Clin Endocrinol Metab1988665106510703129447
   PubMed Web of Science ®Google Scholar
• SalamehWBhasinSSteinerBMcAdamsLAPetersonMSwerdloffRMarked suppression of gonadotropins and testosterone by an antagonist analog of gonadotropin-releasing hormone in menFertil Steril19915511561641898888
   PubMed Web of Science ®Google Scholar
• BagatellCJConnPMBremnerWJSingle-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy menFertil Steril19936046806858405525
   PubMed Web of Science ®Google Scholar
• BagatellCJRivierJEBremnerWJDose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal menFertil Steril19956411391457789550
   PubMed Web of Science ®Google Scholar
• KlingmullerDSchepkeMEnzweilerCBidlingmaierFHormonal responses to the new potent GnRH antagonist CetrorelixActa Endocrinol (Copenh)1993128115188447189
   PubMedGoogle Scholar
• BroquaPRivierePJConnPMRivierJEAubertMLJunienJLPharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelixJ Pharmacol Exp Ther200230119510211907162
   PubMed Web of Science ®Google Scholar
• DebruyneFBhatGGarnickMBAbarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancerFuture Oncol20062667769617155895
   PubMedGoogle Scholar
• PR NewswireFDA approves Ferring Pharmaceuticals’ Degarelix (generic name) for the treatment of advanced prostate cancerPR Newswire, Europe Ltd2008 Available from: http://www.prnewswire.co.uk/cgi/news/release?id=245656; Accessed Mar 2 2009.
   Google Scholar
• JiangGStalewskiJGalyeanRGnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6J Med Chem200144345346711462984
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment report for Firmagon (Doc. Ref: EMEA/CHMP/635761/2008). Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/firmagon/H-986-en6.pdf; Accessed Apr 28 2009.
   Google Scholar
• KoechlingWEffect of various GnRH antagonists on histamine release from human skinPoster presented at the 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction2005 Nov 2Salzburg, Austria
   Google Scholar
• AgersoHKoechlingWKnutssonMHjortkjaerRKarlssonMOThe dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogsEur J Pharm Sci200320333534014592699
   PubMed Web of Science ®Google Scholar
• DoehnCSommerauerMJochamDDrug evaluation: Degarelix – a potential new therapy for prostate cancerIDrugs20069856557216871466
   PubMed Web of Science ®Google Scholar
• Degarelix US prescribing information2008 Available from: http://www.fda.gov/cder/foi/label/2008/022201lbl.pdf; Accessed Apr 28 2009.
   Google Scholar
• BalchenTAgersoHOlesenTKJensenJKSenderovitzTPharmacokinetics, pharmacodynamics, and safety of a novel fast-acting gonadotropin-releasing hormone receptor blocker, degarelix, in healthy menPoster presented at the 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction2005 Nov 2Salzburg, Austria
   Google Scholar
• IversenPVan PoppelHTammelaTDetermining the optimal initiation and maintenance dose of degarelix for hormone therapy of prostate cancer patientsPoster presented at the 28th Congress of the Société Internationale d’Urologie2006 Nov 12–15Cape Town, South Africa
   Google Scholar
• Van PoppelHTombalBde la RosetteJJPerssonBEJensenJKKoldOTDegarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase II dosage-finding study in the treatment of prostate cancerEur Urol200854480581318538469
   PubMed Web of Science ®Google Scholar
• GittelmanMPommervillePJPerssonBEJensenJKOlesenTKA 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North AmericaJ Urol200818051986199218801505
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• TombalBMillerKBoccon-GibodLAdditional analysis of the secondary endpoint of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in patients with prostate cancer segmented by baseline characteristicsEur Urol20091120 [Epub ahead of print].
   Web of Science ®Google Scholar
• JungKLeinMStephanCComparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implicationsInt J Cancer2004111578379115252851
   PubMed Web of Science ®Google Scholar
• DamberJETammelaTAbrahamssonPAComparing testosterone and PSA for different baseline testosterone concentrations during initiation of degarelix and leuprolide treatment [abstract]Eur Urol2009Suppl 8130
   Web of Science ®Google Scholar
• SchröderFHTombalBMillerKChanges in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyBJU Int20091113 [Epub ahead of print].
   Web of Science ®Google Scholar
• IversenPJensenJKOlesenTKPerssonBEPhase III trial of degarelix vs leuprolide: comparing safety and tolerabilityPresented at the World Congress on Controversies in Urology2009 Feb 5Lisbon, Portugal Abstract 618148.
   Google Scholar
• CassilethBRSolowayMSVogelzangNJQuality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study GroupQual Life Res1992153233291299464
   PubMedGoogle Scholar
• GomellaLGContemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issuesBJU Int200799Suppl 1252917229166
   PubMed Web of Science ®Google Scholar
• MichaelsonMDCotterSEGargolloPCZietmanALDahlDMSmithMRManagement of complications of prostate cancer treatmentCA Cancer J Clin200858419621318502900
   PubMed Web of Science ®Google Scholar
• GleaveMKlotzLTanejaSSThe continued debate: intermittent vs continuous hormonal ablation for metastatic prostate cancerUrol Oncol2009271818619111804
   PubMed Web of Science ®Google Scholar
• GerberGSZagajaGPRayPSRukstalisDBTransdermal estrogen in the treatment of hot flushes in men with prostate cancerUrology20005519710110654902
   PubMed Web of Science ®Google Scholar
• LoprinziCLMichalakJCQuellaSKMegestrol acetate for the prevention of hot flashesN Engl J Med199433163473528028614
   PubMed Web of Science ®Google Scholar
• LoprinziCLPisanskyTMFonsecaRPilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivorsJ Clin Oncol1998167237723819667254
   PubMed Web of Science ®Google Scholar
• LoprinziCLBartonDLCarpenterLAPilot evaluation of paroxetine for treating hot flashes in menMayo Clin Proc200479101247125115473404
   PubMed Web of Science ®Google Scholar
• WidmarkAFossaSDLundmoPDoes prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3Urology200361114515112559286
   PubMed Web of Science ®Google Scholar
• SaltzsteinDSieberPMorrisTGalloJPrevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozoleProstate Cancer Prostatic Dis200581758315685254
   PubMed Web of Science ®Google Scholar
• LeinMWirthMMillerKSerial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progressionEur Urol20075251381138717321667
   PubMed Web of Science ®Google Scholar
• SmithMRMcGovernFJZietmanALPamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancerN Engl J Med20013451394895511575286
   PubMed Web of Science ®Google Scholar
• RyanCWHuoDBylowKSuppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acidBJU Int20071001707517552955
   PubMed Web of Science ®Google Scholar
• LebretTBouregbaARoles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapyBJU Int2008102101419142418549431
   PubMed Web of Science ®Google Scholar
• AndersonJDegarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancerFuture Oncol20095443344319450172
   PubMed Web of Science ®Google Scholar